Results 11 to 20 of about 3,556,677 (271)

Cytokine release syndrome [PDF]

open access: yesJournal for ImmunoTherapy of Cancer, 2018
During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific T-cell engaging (BiTE) single-chain antibody ...
Alexander Shimabukuro-Vornhagen   +8 more
doaj   +11 more sources

Cytokine Release Syndrome: Current Perspectives

open access: yesImmunoTargets and Therapy, 2019
Hemant Murthy,1 Madiha Iqbal,1 Julio C Chavez,2 Mohamed A Kharfan-Dabaja1 1Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA; 2Department of Malignant Hematology, Moffitt Cancer Center, Tampa,
Murthy H   +3 more
doaj   +7 more sources

Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19

open access: yes, 2022
Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR ...
Chakkapong Burudpakdee (11247636)   +25 more
core   +12 more sources

Cytokine Release Syndrome: An Overview on its Features and Management

open access: yesJournal of Pure and Applied Microbiology, 2019
Cytokine release syndrome (CRS) is a life threatening toxicity associated numerous immunotherapeutic techniques involving monoclonal antibodies, bispecific antibodies and adoptive T cell therapies. It is also referred as infusion reaction that results in
Shailza Shreshtha   +3 more
doaj   +2 more sources

Cytokine release syndrome and tumor lysis syndrome in a multiple myeloma patient treated with palliative radiotherapy: A case report and review of the literature

open access: yesClinical and Translational Radiation Oncology, 2022
We present the case of a 53-year-old woman treated with analgesic radiotherapy for a multiple myeloma bone lesion of the forearm. After a first fraction of 5 Gray (Gy), she presented with an acute respiratory syndrome with fever a few hours after the ...
Axel Cailleteau   +5 more
doaj   +2 more sources

Atypical cytokine release syndrome induced by carboplatin: The first described case report [PDF]

open access: yesInternational Journal of Immunopathology and Pharmacology
Introduction Hypersensitivity reactions to carboplatin include type I reactions, mixed reactions, and delayed reactions. Case report We report a case of an atypical cytokine release syndrome induced by carboplatin in a patient with breast carcinoma ...
Maria Cruz Torres Górriz MD, PhD   +4 more
doaj   +2 more sources

Lost in translation: why cytokine release syndrome reporting fails clinical trials [PDF]

open access: yesJournal for ImmunoTherapy of Cancer
Cytokine release syndrome (CRS) is among the most frequently reported adverse events in trials of immune-cell-engaging therapies, yet its identification, grading, and reporting remain inconsistent across sponsors and investigators, driving overly ...
Stephane Champiat
doaj   +2 more sources

Cytokine release syndrome after bronchoalveolar lavage

open access: yesBMC Pulmonary Medicine, 2023
Background Immunosuppressed bone marrow transplant patients with pulmonary infiltrates routinely undergo bronchoscopy with bronchoalveolar lavage (BAL) to investigate potential etiologies.
Margaret Guerriero   +3 more
doaj   +3 more sources

DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndrome [PDF]

open access: yesFrontiers in Molecular Medicine
Cytokine release syndrome is a serious complication of chimeric antigen receptor-T cell therapy and is triggered by excessive secretion of inflammatory cytokines by chimeric T cells which could be fatal. Following an inquiry into the molecular mechanisms
Grace Haroun, Erlinda M. Gordon
doaj   +2 more sources

Cytokine release syndrome treated with tocilizumab following ipilimumab–nivolumab combination therapy in advanced renal cell carcinoma

open access: yesIJU Case Reports
Introduction Cytokine release syndrome is a rare but potentially life‐threatening complication of immune checkpoint inhibitor therapy. Its occurrence in renal cell carcinoma treated with combination therapy is less recognized and poses significant ...
Toru Inoue   +6 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy